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The objective of the present work is to study the dissolution behavior of olanzapine from its solid 
dispersions with mannitol. Solid dispersions were prepared by melt dispersion method and characterized by 
phase solubility studies, drug content and in vitro dissolution studies. The best releasing dispersions were 
selected from release data, dissolution parameters and their release profiles. Solid state characterization 
techniques like Fourier transform infrared (FT-IR) spectroscopy, X-ray diffractometry, differential 
scanning calorimetry, near-infrared and Raman spectroscopy were used to characterize the drug in 
selected dispersions. The dispersions were also evaluated by wettability studies and permeation studies. 
The results of phase solubility studies and the thermodynamic parameters indicated the spontaneity and 
solubilization effect of the carrier. The release study results showed greater improvement of drug release 
from solid dispersions compared to pure drug, and the release was found to increase with an increase in 
carrier content. The possible mechanism for increased release rate from dispersions may be attributed to 
solubilization effect of the carrier, change in crystal quality, phase transition from crystalline to amorphous 
state, prevention of agglomeration or aggregation of drug particles, change in surface hydrophobicity of 
the drug, and increased wettability and dispersability of the drug in dissolution medium. The suggested 
reasons for increased release rate from dispersions were found to be well supported by results of solid 
state characterization, wettability and permeation studies. The absence of any interaction between the 
drug and the carrier was also proved by FT-IR analysis. 
Uniterms: Olanzapine. Mannitol. Solid dispersions.
O objetivo do presente trabalho é estudar o comportamento de dissolução da olanzapina a partir de 
suas dispersões sólidas de manitol. As dispersões sólidas foram preparadas por dispersão por fusão 
e caracterizadas por estudos de solubilidade de fase, conteúdo de fármaco e dissolução in vitro. As 
melhores dispersões quanto à liberação foram selecionadas a partir dos dados de liberação, parâmetros 
de dissolução e perfis de liberação. Técnicas de caracterização de estado sólido como espectroscopia no 
infravermelho pela transformada de Fourier (FTIR), difratometria de raios X, calorimetria de varredura 
diferencial, infravermelho próximo e espectroscopia Raman foram utilizadas para caracterizar os 
fármacos a partir das dispersões selecionadas. As dispersões foram, também, avaliadas pelos estudos 
de capacidade de umedecimento e permeação. Os resultados dos estudos de solubilidade de fase e os 
parâmetros termodinâmicos indicaram a espontaneidade e o efeito de solubilização do transportador. 
Os resultados dos estudos de liberação mostraram maior aperfeiçoamento da liberação do fármaco das 
dispersões sólidas, comparativamente à do fármaco puro, e descobriu-se que a liberação aumenta com 
o aumento do conteúdo de transportador. O mecanismo possível para o aumento da taxa de liberação 
das dispersões pode ser atribuído ao efeito de solubilização do transportador, mudança da qualidade 
do cristal, transição de fase cristalina para estado amorfo, prevenção da aglomeração ou agregação das 
partículas do fármaco, mudança na superfície de hidrofobicidade do fármaco e aumento da capacidade de 
umedecimento e dispersividade do fármaco no meio de dissolução. As razões sugeridas para o aumento 
da taxa de liberação a partir das dispersões foram apoiadas pelos resultados da caracterização do estado 
sólido, capacidade de umedecimento e pelos estudos de permeação. A ausência de qualquer interação 
entre o fármaco e o transportador foi, também, comprovada pela análise no FTIR.
Unitermos: Olanzapina. Manitol. Dispersões sólidas.
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INTRODUCTION
The dissolution of a drug from its solid oral dosage 
forms depends upon its release from the dosage form and 
its subsequent mixing into physiological fluids. It has been 
estimated that nearly 35-40% of the drugs suffer from poor 
aqueous solubility, thereby affecting their absorption from 
the gastrointestinal tract, which leads to poor oral bioavail-
ability, high intra- and inter-subject variability, increase 
in dose, reduction in therapeutic efficiency and finally 
failure in formulation development (Lipinski, 2002). The 
development of solid dosage forms for water-insoluble 
drugs has been a major challenge for pharmaceutical sci-
entists for decades. Various formulation strategies such 
as micronisation, micellar solubilization, complexation, 
dendrimers for drug solubilization, formation of solid 
solutions or dispersions with hydrophilic carriers, self-
microemulsifying drug delivery systems, spray drying, 
nano approaches, pro-drug approaches and salt synthesis 
(Pinnameni et al., 2002) have been developed to increase 
the dissolution rate of water-insoluble drugs.
An attractive possibility is employing a simple solid 
dispersion technique making use of various hydrophilic 
carriers (Chiou, Reigelmann, 1971; Dhirendra et al., 2009; 
Ansu, Jain, 2011). Solid dispersions (SDs) are defined 
as the dispersion of one or more active ingredients in an 
inert hydrophilic carrier or matrix in a solid state, and are 
prepared by the fusion, solvent or solvent-fusion method 
(Chiou, Reigelmann, 1971). This technique enables re-
ducing particle size to a nearly molecular level, offers a 
variety of processing and excipient options that allow for 
flexibility when formulating oral delivery systems of poor 
water-soluble drugs that are cost-effective and significant-
ly reduced in dosage (Serajuddin, 1999; Dhirendra et al., 
2009). It has been widely demonstrated that a hydrophilic 
carrier dissolves rapidly, exposing the drug particles to 
the dissolution medium as fine particles facilitating quick 
dissolution and absorption.
The mechanisms for increased dissolution rate may 
include reduction of crystallite size, solubilization effect 
of the carrier, absence of aggregation of drug crystallites, 
improved wettability and dispersability of a drug from 
the dispersion, dissolution of the drug in the hydrophilic 
carrier or conversion of the drug to an amorphous state 
(Craig, 2002; Biswal et al., 2008).
Schizophrenia is a severe non-curable illness of the 
brain with serious consequences if not properly treated and 
kept under control. It is the most common form of severe 
mental illness. Olanzapine (OLZ;2-methyl-4-(4-methyl-
1-piperazinyl)-10H-thieno-[2,3-b],[1,5]benzodiazepine) 
is a relatively new benzodiazepine atypical antipsychotic 
medication, which belongs to the class of the thienoben-
zodiazepines and has proven efficacy against the positive 
and negative symptoms of schizophrenia, bipolar disor-
der and other forms of psychosis. It exhibits poor water 
solublility and belongs to Biopharmaceutic Classification 
System (BCS) class II of drugs (low solubility and high 
permeability), highly bound to plasma protein (about 93%) 
(Callaghan et al., 1999; Ayala et al., 2006). Following oral 
administration, Cmax is reached within 5–6 h of dosing. 
OLZ undergoes extensive pre-systemic metabolism in the 
liver, resulting in relatively very low oral bioavailability 
(Cheng et al, 2000; Di NunZio et al., 2008). The objective 
of this work is to enhance the aqueous solubility of poorly 
water-soluble drug OLZ by adopting a solid dispersion 
approach using mannitol as the hydrophilic carrier and to 
physico-chemically characterize the in vitro dissolution 
behavior of the solid dispersions.
MATERIAL AND METHODS
Material
OLZ was received as a gift sample from Unichem 
Laboratories (Mumbai, India). Mannitol was purchased 
from were SD Fine Chemicals Ltd. (Mumbai, India). So-
dium hydroxide, potassium dihydrogen orthophosphate, 
microcrystalline cellulose (DC grade) and magnesium 
stearate were also procured from SD Fine Chemicals Ltd. 
(Mumbai, India). All other solvents and reagents used were 
of analytical grade.
Methods
Dispersion method
A series of solid dispersions were prepared using a 
varying ratio of the carrier (mannitol). The level of OLZ 
was kept constant in all the dispersions. The drug:carrier 
ratios tried were 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10. OLZ was 
dissolved in absolute ethanol to get a clear solution. The car-
rier was powdered well in a mortar. The OLZ solution was 
then added to the powdered carrier with constant trituration. 
The wet solid mixture was dried at 60 °C for 6 h. The dried 
mass was kept in a dessicator for 12 h. Then the dried mass 
was powdered and sifted through sieve no.100. The samples 
are then stored in dessicator until further use (Chowdhary, 
Rao, 2000; Masataka et al., 2002; Markus et al., 2008).
Phase solubility studies
Phase solubility studies were carried out by adding 
excess amount of OLZ to 25 mL of aqueous solutions 
containing increasing amounts of carrier (1:1 to 1:10) 
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in screw-capped bottles and shaken in an orbital shaker 
(Remi Ltd, Mumbai) and incubated at 25 °C and 37 °C for 
24 h. Samples with pure drug and water was used as con-
trol. After 24 h, the solutions were filtered using a What-
man filter paper (0.45 µm, 13 mm, Whatman, USA). The 
filtrate was diluted and analyzed spectrophotometrically at 
259 nm (1700 UV-Vis Shimadzu, Japan). The solubility of 
OLZ in various carriers was calculated using the standard 
curve [OD=0.1149 × concentration – 0.0031]. The data 
were used in phase solubility analysis to calculate vari-
ous thermodynamic parameters such as ∆H, ∆S and ∆G 
(Higuchi, Connors, 1965; Arias et al., 1999; Cirri et al., 
2004; Biswal et al., 2008).
Phase solubility analysis
· Stability constant (Biswal et al., 2008; Singh et al., 2009)
The value of apparent stability constant (Ka) of 
drug–carrier combinations were computed from the phase 
solubility profiles as described below:
  Eq. 1
Gibbs energy (∆G) was calculated using the formula
 DG = –RT ln Ka  Eq. 2
where R is the universal gas constant (8.313 J/mol K), T 
the temperature, and Ka the stability constant.
· Enthalpy
The enthalpy change in the systems was calculated 
from Van’t Hoff equation:
  Eq. 3
where R is the universal gas constant (8.313 J/mol K), Ka 
the stability constant, and dT the difference in temperature 
(Kelvin).
· Entropy
The entropy of the system was calculated from the 
equation
   Eq. 4
where ∆H is the enthalpy and ∆G the entropy.
Drug content
The assay of a weighed amount of solid disper-
sions was carried out to determine the drug content. The 
weighed samples were dissolved in 10 mL of analytical 
media and stirred by a vortex mixer. The solutions were 
filtered using a Whatman filter paper (0.45 µm, 13 mm, 
Whatman, USA). Then the filtrate was diluted suitably 
and the content was estimated spectrophotometrically 
(UV-1700, Shimadzu, Japan) at 259 nm using the standard 
curve, applying a validated method (data not shown). 
In vitro dissolution studies
The in vitro dissolution study of all solid dispersions 
of OLZ in mannitol was carried out on USP dissolution 
apparatus (Campbell Electronics, Mumbai) and the results 
were compared with those for pure OLZ. The dissolu-
tion vessels contained 900 mL of 0.1 N HCl maintained 
at 37 °C ± 0.5 °C and paddle speed set at 50 rpm. Solid 
dispersions equivalent to 20 mg of OLZ were added to the 
dissolution medium in a powder form. Then, 5 mL samples 
were withdrawn at 5, 10, 20, 30, 40, 50 and 60 min from the 
dissolution medium through a graduated pipette equipped 
with plastic tube end closed with a cotton plug. The pres-
ence of cotton plug allows only the dissolved OLZ to be 
collected and filters all the carrier components. The with-
drawn sample was replenished with 5 mL of fresh media. 
The withdrawn samples were analyzed for OLZ content 
by measuring the absorbance at 259 nm using UV-visible 
spectrophotometer (UV-1700, Shimadzu, Japan). Three 
such determinations were carried out for each formulation. 
The content of OLZ was calculated from the standard curve 
[OD=0.1149 × concentration+ 0.001(R2 = 0.9999; 
p > 0.001). The in vitro dissolution parameters such as cu-
mulative per cent drug release and dissolution parameters 
such as amount released (Q), per cent dissolution efficiency 
(% DE), dissolution rate constant (DRC), relative dissolu-
tion rate (RDR), dissolution half life (t50%) and time taken 
to release 85% of drug (t85%) were calculated by applying 
release data into various equations given below (Cirri et al., 
2004; Biswal et al., 2008; Singh et al., 2009).
Dissolution half-life (t50%)
Time taken to release 50% of drug was calculated by
  Eq. 5
Relative dissolution rate (RDR)
It is the ratio of the drug released from the samples 
with respect to pure drug at specific time intervals.
Dissolution efficiency (% DE)
It can be defined as the area under the dissolution 
curve up to a certain time. It is measured using the trap-
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ezoidal method and is expressed as a percentage of the area 
of the rectangle divided by the area of 100% dissolution 
in the same time:
  Eq. 6
Dissolution rate constant (DRC)
A plot of log % drug unreleased versus time was 
drawn and the slope was calculated using MS Excel 2007 
computer programme. Dissolution rate constant was cal-
culated from the equation 
 DRC = Slope * 2.303 Eq. 7
Release kinetics
To study the release kinetics of the drug from the 
solid dispersions, the release data were fitted in to the fol-
lowing equations.
Zero order (K0)
 Qt = Q0 + K0t Eq. 8
where Qt is the amount of drug released at time t, Q0 the 
amount of drug in solution at time t=0 (usually Q0=0) and 
K0 is zero-order release constant.
First order constant (K1)
  Eq. 9
where Qt is the amount of drug released in time t, Q0 = 
amount of drug in solution at time t=0 (usually Q0=0) and 
K1 is the first-order release constant. 
Higuchi model
 Mt = K√t Eq. 10 
where Mt is the amount of drug dissolved at particu-
lar time t, K the Higuchi release constant.
Hixson Crowell model 
  Eq. 11
where W0 is the weight of the drug taken at time t=0 and 
Wt is the weight of the drug taken at time t.
Further, in order to better characterize the drug 
release behavior from the dispersions, the Korsemeyer-
Peppas empirical model was applied:
  Eq. 12
where Qt/Q∞ fractional release of drug at time t, kKP a 
constant comprising the structural characteristics of the 
formulation and n (the release component) a parameter 
indicative of the mechanism of drug release. For the 
particular case of delivery system, n ≤ 0.5 corresponds 
to Fickian release (case I), 0.5 < n < 1.0 to an anomalous 
(non-Fickian) transport, n=1 to a zero-order release kinet-
ics (case II) and n >1 to a super case II transport (Costa, 
Lobo, 2001; Hamid et al., 2006).
Solid State characterization
Fourier Transform Infrared Spectroscopic Studies (FT-
IR)
FT- IR spectra of pure OLZ, carriers, physical mix-
tures of drug and carrier (1:1) and optimized solid disper-
sions were carried out using FTIR spectrophotometer with 
KBr disc (Jasco - FTIR -1700 spectrophotometer, Japan). 
All the samples, viz. OLZ, mannitol and physical mixtures 
(PMs) and solid dispersions, were analyzed in a similar 
manner. Physical mixtures were prepared by blending 
individual components in a glass pestle mortar.
X-ray Diffraction Studies (X-RD)
Diffraction patterns (X-ray diffractometer (Philips, 
Finland), 40 kV, 30 mA generator with a Cu-Kα radiation 
tube) of the pure drug, physical mixtures and selected 
solid dispersions were scanned over 2Ø range from 2 °C 
to 50 °C at the rate of 2 °C per min at 0.02° at 2Ø step size.
Differential scanning calorimetry (DSC) studies
Thermal analysis was carried out using differential 
scanning calorimeter (Q 10 DSC TA, Instruments, Waters 
Inc., Newcastle, USA) with a liquid nitrogen cooling 
accessory. The analysis was performed under purge of 
nitrogen gas (50 cc/min). High-purity indium was used to 
calibrate the heat flow and heat capacity of the instruments. 
The sample (5–10 mg), placed in flat-bottomed aluminum 
pan, was firmLy capped with a lid to provide an adequate 
seal. The sample was heated from ambient temperature 
to 400 °C at pre-programmed heating rate of 10 °C min–1.
Near-infrared (NIR) analysis
NIR spectra of the pure drug and selected samples 
were recorded using a FT-IR spectrometer (Jasco FT-IR, 
Japan) in diffuse reflectance mode (DRS). The samples 
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were scanned in the wavelength range of 800–2000 nm 
and absorbance was measured in transmittance mode.
Confocal Raman spectroscopic analysis 
The Raman spectra of samples and pure drug were 
recorded using confocal Raman spectrophotometer (WI-
TEC Alpha 300, Confocal Raman Nd:YAG laser (532 nm, 
USA)). 
Wetting studies
Formulation of tablets
As per the results of the in vitro release studies, the 
solid dispersion that had the highest concentration of man-
nitol was selected as the best releasing solid dispersion 
from the samples. The tablets of pure OLZ and selected 
solid dispersions (OMAN 10) were formulated by us-
ing 20 mg of pure OLZ and solid dispersions equivalent 
to 20 mg of OLZ. Each tablet weighed around 250 mg. 
Sufficient quantity of microcrystalline cellulose (diluent) 
and magnesium stearate (lubricant) were added and the 
resulting product mixed well in a mortar. The mixture was 
directly compressed in a 10-station rotary tablet punching 
machine (Rimek, Ltd., Mumbai, India) at a compression 
pressure of 5 kg/cm2. The wetting studies were carried out 
only on the tablets made from pure drug and the selected 
solid dispersions. 
Wetting time studies
Five circular tissue papers were placed in a petri 
dish 10 cm in diameter. Ten mL of 0.5% methylene blue 
solution, a water-soluble dye, was added to the petri dish. 
The dye solution was used to identify complete wetting 
of the tablet surface. A tablet was carefully placed on the 
surface of the tissue paper in the petri dish at ambient 
temperature. The time required for water to reach the 
upper surface of the tablets and to completely wet them 
was noted as the wetting time. These measurements were 
carried out in triplicate. Wetting time was recorded using a 
digital watch (Gohel, Patel, 2000; Sunilkumar et al., 2008; 
Adel et al., 2009).
Water absorption ratio
The weight of the tablet prior to placement in the 
petri dish was noted (Wb) using a Metler Toledo Digital 
balance. The wetted tablet was removed and reweighed 
(Wa). Water absorption ratio (R) was then determined using 
Eq. 10 (Sunilkumar et al., 2007; Adel et al., 2009).
  Eq. 13
In vitro dispersion studies
A tablet was added to 10 mL of phosphate buffer pH 
7.4 at 37 °C. The time required for complete dispersion 
was noted. Three such determinations were carried out 
(Adel et al., 2009; Shoukri et al., 2009).
Permeation studies
Preparation of egg membrane
The outer shell membrane of the egg of Gallus 
Domesticus just located inside the shell exactly under 
the hard calcified layer was prepared by immersing the 
egg in 0.01 N HCl for 6 h to dissolve the calcified layer. 
The membrane was cut cautiously to expel the contents 
of the egg and washed with normal saline solution. The 
inner membrane was repeatedly washed with water and 
stored in distilled water (Mehdi et al., 2006; Corti et al., 
2009).
Preparation of onion membrane
The middle membrane of the Allium Cepa L. (onion) 
was peeled or separated with caution by gradual applica-
tion of water in filler to avoid damage to the membrane. 
The stripped membranes (3 cm2) without any crack or 
orifice were selected and stored in cold water until further 
use (Mehdi et al., 2006).
Preparation of tomato membrane
Tomatoes were boiled in hot water for about 15 min. 
The softened outer layer of tomato was removed carefully 
and repeatedly washed with water to remove the fleshy 
TABLE I - Composition of tablets for wetting studies
Composition Olanzapine (mg) OMAN 10 (mg)
OLZ 20 –
Selected SD (OMAN 10) – ≡ 20 mg of olanzapine (217 mg of SD)
Microcrystalline cellulose 223 26
Magnesium stearate 7 7
Total 250 250
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parts of tomato. The washed membranes were stored in 
cold water until further use (Mehdi et al., 2006).
Through natural membrane
All the membranes were inspected by a microscope 
to ensure their integrity and uniformity. Their thickness 
was measured by a caliper, and membranes that had 
thickness similar to a cellophane membrane were used 
for further studies. The required length of egg, onion or 
tomato membrane was cut and tied or glued to the bottom 
(grounded) layer of the diffusion cell with a thread to form 
an inner compartment.
Ten mL of 0.1 N HCl were added to the inner com-
partment and placed in a beaker containing 100 mL of 
0.1 N HCl, which acts as an outer compartment. Care was 
taken to make sure that the level of media in both compart-
ments is equal. A magnetic bead was added to the outer 
compartment to stir the contents during the studies. The 
entire assembly was placed in a magnetic stirrer (Remi 
Ltd, Mumbai, India) and temperature was maintained 
at 37 ± 1 °C. The weighed amount of the pure drug was 
added to the inner compartment of the diffusion cell and 
the studies were performed for duration of 30 min. At 
predetermined time intervals, samples were withdrawn 
and the same volume of media was replenished to maintain 
the sink volume. The solutions were suitably diluted and 
the absorbance was measured spectrophotometrically at 
259 nm (UV-1700, Shimadzu, Japan). The procedure was 
repeated with the selected solid dispersions (OMAN10) 
and with each of the membranes (egg, onion, tomato, cel-
lulose acetate and cellulose nitrate) (Mehdi et al., 2006).
Through cellulose nitrate and cellulose acetate 
Cellulose acetate and cellulose nitrate membrane 
were procured as readymade membranes and rinsed in 
distilled water prior to studies. The cellulose nitrate and ac-
etate membrane were glued to the bottom (grounded) layer 
of the diffusion cell and the procedure was repeated in the 
same way as the diffusion studies were performed using 
egg and other natural membranes (Mehdi et al., 2006).
The apparent permeability coefficient (Papp) was 
calculated using the following equation:
  Eq. 14
where dq/dt is the linear appearance rates of drug in the 
receiver solution during sink conditions, A is the surface 
area of the membrane and C0 the initial drug concentra-
tion in donor compartment (Mehdi et al., 2006; Corti, et 
al., 2005).
Statistical analysis
The difference in the in vitro dissolution profile and 
various dissolution parameters was evaluated statistically. 
The data were tested by two-way analysis of variance. 
RESULTS AND DISCUSSION
Physico-chemical characterization
Phase solubility studies
Phase solubility studies were conducted to determine 
the effect of temperature, solubilization effect of the carrier 
and the spontaneity of solubilizing process when the drug 
is physically mixed with mannitol. The thermodynamic 
parameters of OLZ and its physical mixtures are shown 
in Table II. The solubility of OLZ was found to show a 
linear increase with an increase in the amount of carrier 
and temperature. These results were found to be in accor-
dance with the well-established formation of weak soluble 
complexes (Cirri et al., 2004; Biswal et al., 2008). It is 
also known from earlier studies that the drug molecules 
might have transferred from pure water into the aqueous 
solution of carriers, which was confirmed in our studies 
clearly from the negative thermodynamic parameters like 
∆G and ∆H and positive entropy ∆S of physical mixtures. 
These findings prove the spontaneous nature of the solubi-
lization process. The enhancement of drug solubility in the 
hydrophilic carrier could also be equally well explained by 
co-solvency effect of the carrier. It was also suggested that 
the hydrophilic carriers may interact with the drug mol-
ecules by electrostatic bonds and other types of bonding 
such as van der Waals forces, and this was the likely cause 
for the formation of weakly soluble complexes. The slopes 
of straight linear relationship was assumed as indicative of 
the relative solubilizing efficiency of the carrier (Higuchi, 
Connors, 1965; Arias et al, 1999; Cirri et al., 2004; Biswal 
et al., 2008; Singh et al., 2009).
Drug content
The assayed drug content in all solid dispersions 
was found to be in the range of 98–104%, indicating 
the uniform distribution of the drug in formulations and 
the suitability of the method used for the formulation of 
dispersions.
In vitro dissolution studies
The % cumulative release of pure OLZ was found 
to be 70% in 1 h while solid dispersions showed a signifi-
cant improvement in release rate in the same period. The 
percentage of drug release from SDs was found to increase 
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TABLE II - Thermodynamic parameters of olanzapine physical mixtures with carriers
S. No Carrier Temp. (°C) Slope Intercept Ka (M
–1) ∆G (kJ/mol)
∆H 
(kJ/mol)
∆S 
(J/mol K)
1 MAN 25 –8.46 3.797 –0.236 –1.958 –1.955 1.951
37 –118.9 10.59 –1.188 –0.787 –0.787 0.784
gradually as the amount of carrier in solid dispersions was 
increased from 1:1 to 1:10 (Figure 1).The in vitro release 
data of sample solid dispersions showed a significant dif-
ference (p > 0.001) in the release rate in comparison with 
pure OLZ. The in vitro dissolution parameters of the SDs 
are presented in Table III. It was found that parameters like 
% cumulative release, amount of drug released, % DE and 
RDR values were found to exhibit a linear increase with 
increase in the amount of carrier in dispersions. The other 
parameters like DRC, t50% and t85 % values were found to 
decrease with an increase in carrier fraction.
The correlation plot of % DE and t50% is shown in 
Figure 2. The % DE values were found to increase from 
59.61% (for pure OLZ) to 80.73% (for solid dispersions) 
with 1:10 ratio. The dissolution half-life was found to 
decrease from 12.5 (pure OLZ) to 3.5 (for OMAN10), 
and t85% were found to be reduce from 60 min (for pure 
OLZ) to 30 min (for OMAN 10). Based on these find-
ings, it can be inferred that batch OMAN10 was found to 
FIGURE 1 - Dissolution profiles of olanzapine–mannitol SDs 
compared with pure OLZ. All data points represent the mean of 
3 values, n=3. │- OLZ, □- OMAN1, ж-OMAN2, X- OMAN4, 
■-OMAN6, ∆- OMAN8 and ●- OMAN10.
FIGURE 2 - Correlation plot for dissolution efficiency (% DE) 
and dissolution half-life (t50%). ■- Dissolution half-life and □-% 
dissolution efficiency.
exhibit best release behavior than other solid dispersions. 
The order of OLZ drug release from the solid dispersions 
could be ranked as: OMAN10 > OMAN > 8 > OMAN> 6 
> OMAN4 > OMAN2 > OMAN1 > OLZ. 
The difference in t50% and %DE between the pure 
durg and solid dispersions was evaluated statistically. 
When examined by two-way analysis of variance, the t50% 
and % DE data showed significant difference between the 
pure drug and test products (p>0.001). 
The possible reasons for enhanced release rate of 
OLZ from such dispersions could be that hydrophilic car-
rier mannitol forms a hydrophilic diffusion layer around 
the drug particles, altering the hydrophobic surface charac-
teristics, which results in an increased wettability of drug 
within the dissolution medium. The factors like decreased 
particle size, decreased crystallinity and prevention of 
aggregation and agglomeration of the drug by the carrier 
are also indicated as the additional factors responsible for 
the enhanced dissolution rate from the solid dispersions 
(Masataka et al., 2002; Valizadeh et al., 2004; Natalia et 
al., 2005; Nokhodchii et.al., 2007). Earlier studies have 
shown that if the amount of carrier in the dispersion is very 
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high, there is a possibility of the drug being dispersed in 
the molecular form in the carrier structure with reduced 
crystallinity and this phenomenon would have also as-
sisted in increasing the dissolution rate (Arias et al., 1996; 
Masataka et al., 2002; Cirri et al., 2004; Valizadeh et al., 
2004; Nokhodichii et.al., 2007; Karavas et al., 2007).
The release kinetics of the in vitro dissolution data 
(Table IV) and the regression parameters were analyzed 
to ascertain the type of drug release from solid disper-
sions. Since the co-efficient of correlation r value of 
Korsemeyer-Peppas model was found to predominate over 
the r value in other models, the release data were found to 
fit aptly into Korsemeyer-Peppas kinetic model. Further, 
the release exponent n values were found to be well within 
0–0.5, suggesting a Fickian type of drug release from the 
dispersion (Costa, Lobo, 2001; Hamid et al., 2006). The 
possible mechanism suggested for high release of OLZ 
from dispersions was also found to correlate with the find-
ings of release kinetic analysis.
Solid state characterization
FT-IR studies
The FT-IR spectra of OLZ, physical mixtures (1:1) 
and SDs are presented in Figure 3. Pure OLZ showed 
characteristic absorptions at 3239 cm–1 (NH and OH 
stretching), 2929 cm–1 (C–H stretching), 1587 cm–1 (C=C 
stretching), 1421 cm–1 (C=N stretching) and 1287 cm–1 
TABLE III - Dissolution parameters of olanzapine–MAN solid dispersion
Code Composition OLZ:MAN Q05 (mg) Q30 (mg) DE % RDR 05 RDR 30 DRC t50% (min) t85% (min)
OLZ 1:0 9.34 (0.12) 12.15 (0.56) 59.61 – – 0.020 (0.001) 12.5 >60
OMAN1 1:1 9.63 (0.47) 12.57 (0.24) 54.31 1.03 0.89 0.024 (0.001) 6.0 >60
OMAN2 1:2 12.23 (0.24) 13.36 (0.24) 64.82 1.31 1.10 0.023 (0.001) 5.0 >60
OMAN4 1:4 12.83 (0.21) 13.67 (0.09) 66.95 1.37 1.12 0.022 (0.001) 4.5 >60
OMAN6 1:6 12.44 (0.68) 14.38 (0.16) 70.98 1.33 1.18 0.016 (0.001) 4.25 >60
OMAN8 1:8 12.15 (0.12) 16.36 (0.16) 76.35 1.30 1.35 0.007 (0.003) 3.5 44.5
OMAN10 1:10 12.94 (0.35 16.94 (0.12) 80.73 1.39 1.39 -0.016 (0.031) 3.0 30.0
Values in parenthesis indicates standard deviation:
Q05 – Amount released at 05 min (mg)
Q30 – Amount released at 05 min (mg)
% DE – Per cent dissolution efficiency
DRC – Dissolution rate constant
RDR – Relative dissolution rate at specific time intervals
t50 % – Dissolution half-life 
t85% – Time taken to release 85% of drug from dispersions
TABLE IV - Release kinetic parameters of olanzapine–MAN solid dispersions
Code
Zero Order First Order Higuchi Hixson Crowell K-P
r2 K0 r2 Slope K1 r2 Slope r2 Slope r2 n
OLZ 0.796 0.998 0.110 0.009 0.020 0.857 8.24 0.751 0.012 0.993 0.257
OMAN1 0.768 0.819 0.121 0.009 0.021 0.827 8.05 0.703 0.011 0.990 0.258
OMAN2 0.620 0.674 0.177 0.010 0.023 0.637 7.20 0.456 0.009 0.937 0.246
OMAN4 0.646 0.724 0.154 0.009 0.021 0.667 7.60 0.511 0.010 0.947 0.256
OMAN6 0.696 0.845 0.093 0.007 0.016 0.732 8.62 0.629 0.013 0.967 0.284
OMAN8 0.732 0.971 0.021 0.003 0.007 0.778 9.72 0.731 0.017 0.979 0.314
OMAN10 0.775 1.110 0.075 -0.007 -0.016 0.828 10.82 0.877 0.026 0.989 0.342
K0 – Zero-order release constant, K1 – First order release rate constant and n – release exponent
K-P – Korsemeyer Peppas model
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(C–N stretching) (Ayala et al., 2006; 2007; Hiriyanna 
et al., 2008). The characteristic peaks of pure OLZ were 
found to be present in the spectra of PM as well as in 
solid dispersions. This finding reveals the lack of interac-
tion between the drug and the carrier in the samples. It 
was also noticed that the significant peaks of pure drug 
at specific wave number (3239 cm–1) was found to be in 
reduced form, with less sharpness and more broadness 
as the amount of mannitol was increased in the samples. 
These findings clearly prove the reduction of crystallinity 
in the drug molecule present in samples (Ayala et al., 2006; 
Ayala, 2007; Hiriyanna et al., 2008).
X-ray diffraction analysis
X-ray diffraction spectra of pure OLZ, mannitol, 
physical mixture (1:1) and batch OMAN 10 are illustrated 
in Figure 4. The presence of sharp distinct peaks in OLZ 
spectra indicated its high crystallinity. The carrier (man-
FIGURE 3 -FT-IR spectra of pure olanzapine (OLANZ), 
physical mixtures (OMANPM) at 1:1 ratio, solid dispersions 
(SDs) OMAN1, OMAN2, OMAN4, OMAN6, OMAN 8 and 
OMAN10.
FIGURE 4 - XRD spectra of pure olanzapine (OLANZ), 
mannitol (MAN), physical mixtures (OMANPM) at 1:1 ratio 
and solid dispersions (SDs) OMAN 10 at 1:10 ratio.
nitol) spectra exhibited a distinct diffraction pattern with 
prominent peaks at 2Ø of 18.95, 20 and 22.10º (Valizadeh 
et al., 2004; Manish et al., 2007). The principal peaks of 
the drug were found to appear in diffractogram of physical 
mixture in 1:1 ratio, suggesting the absence of interaction 
between the drug and the carrier. The prominent peak of 
OLZ at 2Ø of 5º was found to be reduced in sharpness in 
the diffractogram of the sample OMAN10.
Further the peaks in sample diffractogram was also 
found to possess less peak height, low relative intensity 
and high full width at half-minimum (FWHM) values than 
the peaks corresponding to the pure drug. From these ob-
servations, it can be concluded that the crystalline nature 
of the drug was still maintained, but the relative reduction 
of diffraction intensity of OLZ suggests that the quality of 
the crystal was reduced. These observations confirm the 
reduction of crystallinity of OLZ present in dispersions 
(Arias et al., 1999; Cirri et al., 2004; Valizadeh et al., 2004; 
Nokodichii et al., 2007; Singh et al., 2009).
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Differential scanning calorimetry (DSC) studies
The DSC scans of pure OLZ, PGS and optimized 
solid dispersions (OMAN10) are presented in Figure 5. 
A sharp single endothermic peak appeared for pure OLZ 
with the following parameters: onset at 194.36 °C, peak 
at 196.40 °C, area of 262.56 mJ and ΔH value of 105.023. 
These values clearly indicate its high crystalline nature 
(Ayala et al., 2006; Ayala, 2007).
Two peaks were observed in the sample thermo-
gram: one at 165.95 °C (due to carrier) and a very short, 
reduced endothermic peak at 190.05 °C (of drug) with 
a peak area of 65.96 mJ and increased ΔH value. This 
variation in thermal behavior of selected solid dispersions 
can be attributed to the fact that the reduced crystallinity 
or phase transition (from crystalline to amorphous form) 
had occurred in the drug molecule during the formulation 
of solid dispersions. These changes in the structure of the 
drug molecule might have contributed to the enhanced 
dissolution rate of OLZ from the dispersions (Arias et 
al., 1999; Valizadeh et al., 2004; Nokodichii et al., 2007).
Near-infrared Analysis
The near-infrared spectra of OLZ and optimized 
solid dispersions (OMAN10) are compared in Figure 6. 
The characteristic peaks of pure OLZ appeared at 1141 and 
1581 nm (Ayala et al., 2006; Ayala, 2007). The specific 
peaks of OLZ in spectra of optimized solid dispersions 
were found to be broader in nature and a slight shift in the 
peak position in comparison with the spectra of pure OLZ. 
These findings indicate the reduction of crystallinity of the 
drug present in SDs.
Raman analysis
The Raman spectra of pure OLZ and selected solid 
dispersions (OMAN10) are compared in Figure 7. The 
sharp peaks of OLZ appeared at 2435, 1594, 1517, 1460, 
1224, 1050, 965, 784 and 480 cm–1 positions (Ayala et al., 
2006; Ayala, 2007) in pure drug spectra, which is indica-
FIGURE 5 - DSC thermograms of pure olanzapine, mannitol 
and solid dispersions (SDs) at 1:10 ratio.
FIGURE 6 - Near-infrared spectra of pure olanzapine (OLZ) and 
solid dispersions (SDs) OMAN10.
FIGURE 7 - Raman spectra of olanzapine (OLZ) and SDs 
(OMAN 10).
Physicochemical characterization and in vitro dissolution behavior of olanzapine-mannitol solid dispersions 253
TABLE V - Wettability data of pure olanzapine and selected solid dispersions
Batch Wetting Time (min) Water Absorption Ratio In vitro Dispersion Time (min)
OLZ >60 (2.26) 11.49 (1.14) > 60 (1.12)
OMAN10 18 (2.36) 15.86 (0.96) 18 (0.86)
Values in parenthesis indicates standard deviation (n=3).
tive of its high crystallinity. The characteristic peaks of 
pure OLZ were found to be in much reduced broadness and 
slight shift towards their lower wave numbers in sample 
spectra. These findings clearly suggest that some degree 
of structural changes had taken place in the drug molecule 
when dispersed in hydrophilic carriers.
Wettability studies
The wettability data of pure OLZ and optimized SDs 
(OMAN 10) are shown in Table V. The wetting time and 
in vitro dispersion of pure OLZ was found to be more than 
60 min and water absorption ratio of olanzapine was found 
to about 11.49. It was observed that tablets prepared with 
OLZ did not show any sign of structural changes after 60 
min and it was also found to retain its compactness during 
the in vitro dispersion studies.
These results clearly prove the high hydrophobicity, 
poor wettability and low water absorption potential of 
OLZ (Sunilkumar et al., 2007). The wetting time and in 
vitro dispersion time of sample was found to be 18 min, 
much less than the pure OLZ (more than 60 min). The 
water absorption ratio of sample was found to be higher 
(15.18) than pure OLZ (11.49), indicating the water ab-
sorption potential of mannitol. It was also observed that the 
tablets were found to absorb water slowly and get disinte-
grated into small fragments during the dispersion process. 
These observations confirm the increased wettability in 
samples and also provide a clear Insight into the role of 
hydrophilic carriers in the formulations (Sunilkumar et al., 
2007; Adel et al., 2009).
Permeation Studies
Natural and synthetic membranes
Permeation studies across various natural mem-
branes had been used as a tool to predict the gastrointes-
tinal permeation of drugs. Permeation studies were con-
ducted across natural membranes like onion, tomato, egg 
membrane and synthetic membranes like cellulose acetate 
and cellulose nitrate. The apparent permeation coefficient 
values of pure OLZ and selected solid dispersion batches 
across the tested membranes are determined and tabulated 
in Table VI. The permeation coefficient of the optimized 
solid dispersions across the tested membranes was found 
to be higher than pure OLZ. These findings prove the per-
meation efficiency of the selected solid dispersions and 
the possible reasons attributed to hydrophilic nature of the 
carrier and increased wettability in samples solid disper-
sions (Mehdi et al, 2006; Corti et al., 2006). The possible 
mechanism suggested for its enhanced aqueous solubility 
and release rate are particle size reduction, solubilization 
effect of carrier, change in crystal quality or formation of 
solid solution, change in surface hydrophobicity of drug 
particles and increased wettability due to increased water 
absorption by the carrier. Due to these factors, the drug 
would dissolve fast in gastric secretions, leading to its 
higher dissolution and subsequent absorption. Further the 
membranes in which the permeability studies were con-
ducted were proved to be similar to biological membranes 
and studies across such membranes have been already 
reported in literature and it had been suggested that per-
meation studies across such membranes could be used as 
predictors for increased permeability of the model drug. 
Mechanisms for enhanced release
The possible reasons that might be attributed to 
increased release rate from solid dispersions are particle 
size reduction, solubilization effect of carrier, change in 
crystal quality or formation of solid solution, prevention 
of aggregation or agglomeration of drug particles in dis-
solution medium, change in surface hydrophobicity of 
TABLE VI - Apparent permeation coefficient data of OLZ and 
selected solid dispersions (OMAN10) 
Membrane
Apparent permeation 
coefficient Papp (cm s–1)
OLZ OMAN10
Egg 0.001 0.002
Onion 0.001 0.002
Tomato 0.001 0.002
CA 0.004 0.016
CN 0.015 0.018
Each value represents the mean of three values. 
CA – cellulose acetate, CN – cellulose nitrate.
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drug particles and increased wettability due to increased 
water absorption by the carrier. These postulations were 
well supported by the findings of physicochemical char-
acterization techniques used for evaluation of solid disper-
sions. Further, the suggested reasons for enhanced release 
were found to be in accordance with the earlier published 
reports using hydrophilic carriers (Corrigon, 1985; Leuner, 
Dressman, 2000; Craig, 2002).
CONCLUSION
The approach of the present work was to characteri-
ze the solid dispersion of a BCS Class II drug and study 
its effect on dissolution. The results of the work clearly 
suggest that the solid dispersions formulated with man-
nitol could be developed in fast release dosage forms with 
improved oral absorption and therapeutic efficiency. The 
solid dispersions could be explored further to establish 
pharmacokinetic and pharmacodynamic profiles for real-
izing their full potential. 
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